-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Adcentrx Therapeutics, a biotechnology company focused on the research and development of breakthrough antibody-conjugated drugs ("ADC"), announced the completion of a US$50 million Series A financing
.
The financing will accelerate Adcentrx's strategic layout in the ADC field and provide patients with more treatment options
Adcentrx was founded by a senior team that has been deeply involved in ADC, target biology and pharmaceutical technology production for many years
.
The founder Dr.
"We are very satisfied with the current development progress of the company's proprietary ADC platform and look forward to pushing a batch of innovative drugs into the development stage
.
" said Li Hui, founder and CEO of Adcentrx
"Working with accomplished professionals in the ADC field makes us very excited
.
" Kangqiao Capital Managing Director Jiang Mengjiao said, "In addition to the current pipeline products, we are also very optimistic about the company's prospects for establishing a proprietary ADC platform.